Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2022

View Archived Issues

GTX-0196 shows complete tumor growth suppression in models of AML

Storm Therapeutics divulges new METTL3 inhibitors

New MRGPRX2 antagonists identified at GlaxoSmithKline

PRISM BioLab discovers Notch signaling inhibitors

Leukos Biotech patents serotonin 5-HT1B receptor antagonists

Ingenew BioPharma synthesizes new IL-1beta, IL-6 and TNF-alpha release inhibitors

In times of need, fat cells take on immune functions

Janssen describes discovery of improved Mcl-1 inhibitor JNJ-4355

MJFF grant supports Asceneuron's preclinical evaluation of ASN-51 for Parkinson's disease

Dianthus closes series A financing to support development of antibody complement therapeutics

CRD-1600 demonstrates robust immune modulatory properties in vitro and in vivo

Studies show KRAS G12C inhibitor APG-1842 is potent, bioavailable and highly selective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...